These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment for Lambert-Eaton myasthenic syndrome. Keogh M; Sedehizadeh S; Maddison P Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260 [TBL] [Abstract][Full Text] [Related]
4. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials. Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155 [TBL] [Abstract][Full Text] [Related]
5. Treatment in Lambert-Eaton myasthenic syndrome. Maddison P Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581 [TBL] [Abstract][Full Text] [Related]
6. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports. Schneider I; Kornhuber ME; Hanisch F J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033 [TBL] [Abstract][Full Text] [Related]
7. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. Illa I J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667 [TBL] [Abstract][Full Text] [Related]
8. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. McEvoy KM; Windebank AJ; Daube JR; Low PA N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713 [TBL] [Abstract][Full Text] [Related]
9. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Quartel A; Turbeville S; Lounsbury D Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318 [TBL] [Abstract][Full Text] [Related]
10. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Verschuuren JJ; Wirtz PW; Titulaer MJ; Willems LN; van Gerven J Expert Opin Pharmacother; 2006 Jul; 7(10):1323-36. PubMed ID: 16805718 [TBL] [Abstract][Full Text] [Related]
11. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome. Lee MK; Sunwoo IN; Kim SM J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568 [TBL] [Abstract][Full Text] [Related]
12. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine. Chan KY; Chang RS; Lau VW; Chan ML; Lai T Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750 [TBL] [Abstract][Full Text] [Related]
17. [A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine]. Uekita K; Ishida T; Sekine S; Ishii T; Sato S; Sugawara A; Tachihara M; Watanabe K; Kanazawa K; Saito J; Tanino Y; Munakata M Nihon Kokyuki Gakkai Zasshi; 2009 Jan; 47(1):76-80. PubMed ID: 19198242 [TBL] [Abstract][Full Text] [Related]
18. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Bain PG; Motomura M; Newsom-Davis J; Misbah SA; Chapel HM; Lee ML; Vincent A; Lang B Neurology; 1996 Sep; 47(3):678-83. PubMed ID: 8797464 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643 [TBL] [Abstract][Full Text] [Related]